Organon & Co. (OGN) Competitors

Blueprint Medicines (NASDAQ:BPMC) and Organon & Co. (NYSE:OGN) are both mid-cap medical companies, but which is the better investment? We will contrast the two companies based on the strength of their earnings, institutional ownership, valuation, community ranking, profitability, risk, analyst recommendations, dividends and media sentiment.

Which has more volatility and risk, BPMC or OGN?

Blueprint Medicines has a beta of 0.84, indicating that its share price is 16% less volatile than the S&P 500. Comparatively, Organon & Co. has a beta of 0.58, indicating that its share price is 42% less volatile than the S&P 500.

Does the media prefer BPMC or OGN?

In the previous week, Organon & Co. had 30 more articles in the media than Blueprint Medicines. MarketBeat recorded 41 mentions for Organon & Co. and 11 mentions for Blueprint Medicines. Blueprint Medicines' average media sentiment score of 0.75 beat Organon & Co.'s score of 0.03 indicating that Blueprint Medicines is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Blueprint Medicines	5 Very Positive mention(s)	1 Positive mention(s)	4 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Organon & Co.	2 Very Positive mention(s)	2 Positive mention(s)	34 Neutral mention(s)	3 Negative mention(s)	0 Very Negative mention(s)	Neutral

Do analysts recommend BPMC or OGN?

Blueprint Medicines currently has a consensus price target of $129.35, indicating a potential upside of 0.89%. Organon & Co. has a consensus price target of $18.00, indicating a potential upside of 78.75%. Given Organon & Co.'s stronger consensus rating and higher probable upside, analysts clearly believe Organon & Co. is more favorable than Blueprint Medicines.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Blueprint Medicines	0 Sell rating(s)	16 Hold rating(s)	5 Buy rating(s)	1 Strong Buy rating(s)	2.32
Organon & Co.	1 Sell rating(s)	2 Hold rating(s)	2 Buy rating(s)	1 Strong Buy rating(s)	2.50

Which has higher earnings and valuation, BPMC or OGN?

Organon & Co. has higher revenue and earnings than Blueprint Medicines. Blueprint Medicines is trading at a lower price-to-earnings ratio than Organon & Co., indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Blueprint Medicines	$562.12M	14.73	-$67.09M	-$2.47	-51.91
Organon & Co.	$6.29B	0.42	$864M	$2.88	3.50

Does the MarketBeat Community prefer BPMC or OGN?

Blueprint Medicines received 534 more outperform votes than Organon & Co. when rated by MarketBeat users. Likewise, 66.99% of users gave Blueprint Medicines an outperform vote while only 34.48% of users gave Organon & Co. an outperform vote.

Company	Underperform	Outperform
Blueprint Medicines	Outperform Votes 554 66.99%	Underperform Votes 273 33.01%
Organon & Co.	Outperform Votes 20 34.48%	Underperform Votes 38 65.52%

Is BPMC or OGN more profitable?

Organon & Co. has a net margin of 13.49% compared to Blueprint Medicines' net margin of -13.19%. Organon & Co.'s return on equity of 431.62% beat Blueprint Medicines' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Blueprint Medicines	-13.19%	-77.49%	-20.84%
Organon & Co.	13.49%	431.62%	8.03%

Do institutionals & insiders hold more shares of BPMC or OGN?

77.4% of Organon & Co. shares are held by institutional investors. 4.2% of Blueprint Medicines shares are held by insiders. Comparatively, 2.0% of Organon & Co. shares are held by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company will outperform the market over the long term.

Summary

Organon & Co. beats Blueprint Medicines on 11 of the 18 factors compared between the two stocks.